Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hamsyl Junior
- Development stage
- Unknown
- Lead developer
- Gennova Biopharmaceuticals
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Intravenous
01
Overview
Hamsyl Junior is a pediatric-specific formulation of pegaspargase, a covalent conjugate of Escherichia coli-derived L-asparaginase with monomethoxypolyethylene glycol (mPEG). Developed by Gennova Biopharmaceuticals, it is used as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric patients with acute lymphoblastic leukemia (ALL). The drug functions by depleting systemic levels of the amino acid asparagine; while normal cells can synthesize asparagine, leukemic lymphoblasts lack asparagine synthetase and depend on exogenous sources for protein synthesis, leading to selective apoptosis of cancer cells. Launched in India in March 2024, this formulation provides a 1500 IU pack size (750 IU/mL) specifically designed to reduce drug wastage and ensure appropriate dosing for children's smaller body sizes.
- Brand names
- Hamsyl Junior
- Other names
- pegaspargase
Beyond the preview
Go deeper on Hamsyl Junior.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hamsyl Junior.